**Federal marijuana rescheduling from Schedule I to Schedule III advanced through executive and administrative action in 2026, shaping trader views on timing for broader changes.** In December 2025, President Trump issued an executive order directing expedited completion of the rulemaking process to move marijuana to Schedule III. On April 23, 2026 (effective April 28), the Department of Justice and DEA issued a final order immediately placing FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, while withdrawing prior proceedings and launching a new expedited hearing on full rescheduling of all marijuana. The DEA hearing, focused on evidence for transferring marijuana broadly to Schedule III, began June 29, 2026, and was scheduled to conclude no later than July 15, 2026. Post-hearing steps include potential issuance of a final rule, followed by a publication and effective-date period (typically 30 days or more under the Congressional Review Act for major rules). As of mid-August 2026, market pricing reflects trader assessments of whether these remaining procedural steps, any legal challenges, or further administration actions will meet specific resolution deadlines. Key upcoming catalysts include the DEA’s post-hearing determination and Federal Register publication timeline.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert$796,329 Vol.
31. März 2026
30. September
14%
31. Dezember
28%
$796,329 Vol.
30. September
$0 Vol.
14%
31. Dezember
$186,758 Vol.
28%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Federal marijuana rescheduling from Schedule I to Schedule III advanced through executive and administrative action in 2026, shaping trader views on timing for broader changes.** In December 2025, President Trump issued an executive order directing expedited completion of the rulemaking process to move marijuana to Schedule III. On April 23, 2026 (effective April 28), the Department of Justice and DEA issued a final order immediately placing FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, while withdrawing prior proceedings and launching a new expedited hearing on full rescheduling of all marijuana.
The DEA hearing, focused on evidence for transferring marijuana broadly to Schedule III, began June 29, 2026, and was scheduled to conclude no later than July 15, 2026. Post-hearing steps include potential issuance of a final rule, followed by a publication and effective-date period (typically 30 days or more under the Congressional Review Act for major rules). As of mid-August 2026, market pricing reflects trader assessments of whether these remaining procedural steps, any legal challenges, or further administration actions will meet specific resolution deadlines. Key upcoming catalysts include the DEA’s post-hearing determination and Federal Register publication timeline.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Markt eröffnet: Feb 7, 2026, 5:04 PM ET
Volumen
$796,329Enddatum
31. März 2026Markt eröffnet
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Federal marijuana rescheduling from Schedule I to Schedule III advanced through executive and administrative action in 2026, shaping trader views on timing for broader changes.** In December 2025, President Trump issued an executive order directing expedited completion of the rulemaking process to move marijuana to Schedule III. On April 23, 2026 (effective April 28), the Department of Justice and DEA issued a final order immediately placing FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, while withdrawing prior proceedings and launching a new expedited hearing on full rescheduling of all marijuana.
The DEA hearing, focused on evidence for transferring marijuana broadly to Schedule III, began June 29, 2026, and was scheduled to conclude no later than July 15, 2026. Post-hearing steps include potential issuance of a final rule, followed by a publication and effective-date period (typically 30 days or more under the Congressional Review Act for major rules). As of mid-August 2026, market pricing reflects trader assessments of whether these remaining procedural steps, any legal challenges, or further administration actions will meet specific resolution deadlines. Key upcoming catalysts include the DEA’s post-hearing determination and Federal Register publication timeline.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volumen
$796,329Enddatum
31. März 2026Markt eröffnet
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...**Federal marijuana rescheduling from Schedule I to Schedule III advanced through executive and administrative action in 2026, shaping trader views on timing for broader changes.** In December 2025, President Trump issued an executive order directing expedited completion of the rulemaking process to move marijuana to Schedule III. On April 23, 2026 (effective April 28), the Department of Justice and DEA issued a final order immediately placing FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, while withdrawing prior proceedings and launching a new expedited hearing on full rescheduling of all marijuana. The DEA hearing, focused on evidence for transferring marijuana broadly to Schedule III, began June 29, 2026, and was scheduled to conclude no later than July 15, 2026. Post-hearing steps include potential issuance of a final rule, followed by a publication and effective-date period (typically 30 days or more under the Congressional Review Act for major rules). As of mid-August 2026, market pricing reflects trader assessments of whether these remaining procedural steps, any legal challenges, or further administration actions will meet specific resolution deadlines. Key upcoming catalysts include the DEA’s post-hearing determination and Federal Register publication timeline.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert
Vorsicht bei externen Links.
Vorsicht bei externen Links.
Häufig gestellte Fragen